PDEX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.15% compared to Pro-Dex's net margin of 14.45%. Pro-Dex's return on equity of 21.59% beat Boston Scientific's return on equity of 9.57%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 17.75%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 11.4%. Given that Pro-Dex has higher upside potential than Boston Scientific, analysts believe Pro-Dex is more attractive than Boston Scientific.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Pro-Dex's net income of $2M is lower than Boston Scientific's net income of $674M. Notably, Pro-Dex's price-to-earnings ratio is 22.93x while Boston Scientific's PE ratio is 76.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.56x versus 8.84x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of 12.15% compared to Pro-Dex's net margin of -87.01%. Pro-Dex's return on equity of 21.59% beat Outset Medical's return on equity of -178.08%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 17.75%. On the other hand Outset Medical has an analysts' consensus of $21.75 which suggests that it could grow by 77.55%. Given that Outset Medical has higher upside potential than Pro-Dex, analysts believe Outset Medical is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Outset Medical quarterly revenues of $29.5M. Pro-Dex's net income of $2M is higher than Outset Medical's net income of -$25.6M. Notably, Pro-Dex's price-to-earnings ratio is 22.93x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.56x versus 0.37x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.15% compared to Pro-Dex's net margin of 16.85%. Pro-Dex's return on equity of 21.59% beat Insulet's return on equity of 43.11%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 17.75%. On the other hand Insulet has an analysts' consensus of $313.60 which suggests that it could grow by 22.02%. Given that Insulet has higher upside potential than Pro-Dex, analysts believe Insulet is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Insulet quarterly revenues of $597.5M. Pro-Dex's net income of $2M is lower than Insulet's net income of $100.7M. Notably, Pro-Dex's price-to-earnings ratio is 22.93x while Insulet's PE ratio is 44.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.56x versus 9.17x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 12.15% compared to Pro-Dex's net margin of 11.15%. Pro-Dex's return on equity of 21.59% beat Stryker's return on equity of 14.2%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 17.75%. On the other hand Stryker has an analysts' consensus of $424.26 which suggests that it could grow by 11.93%. Given that Pro-Dex has higher upside potential than Stryker, analysts believe Pro-Dex is more attractive than Stryker.

Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Pro-Dex pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Stryker quarterly revenues of $5.9B. Pro-Dex's net income of $2M is lower than Stryker's net income of $654M. Notably, Pro-Dex's price-to-earnings ratio is 22.93x while Stryker's PE ratio is 51.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.56x versus 6.29x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.